KORU Medical Q2 revenue $12.0M (+18% YoY), net income $0.25M, raises gross margin guidance to 62-64%

KORU Medical Systems, Inc.

Net revenues $12.0M (+18% YoY); gross profit $7.8M (+20%); gross margin 65.1% vs 63.5% prior year.
Net income $0.25M vs net loss ($0.2M) prior year; adjusted EBITDA $0.9M vs $0.3M.
Updated FY2026 guidance: revenue $47.5-$48.5M (15-18% growth), gross margin 62-64%, positive adjusted EBITDA, year-end cash >$7.5M.
Acquired connected monitoring technology asset; withdrew 510(k) for FreedomEDGE with Phesgo in U.S., shifting oncology strategy to higher volume molecules.
Entered multi-year supply agreement; cash $8.3M at quarter end.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.